CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial
Sallman, David A, Kerre, Tessa, Havelange, Violaine, Poiré, Xavier, Lewalle, Philippe, Wang, Eunice S, Brayer, Jason B, Davila, Marco L, Moors, Ine, Machiels, Jean-Pascal, Awada, Ahmad, Alcantar-Orozco, Erik M, Borissova, Rossitza, Braun, Nathalie, Dheur, Marie-Sophie, Gilham, David E, Lonez, Caroline, Lehmann, Frédéric F, Flament, Anne
Published in The Lancet. Haematology (01.03.2023)
Published in The Lancet. Haematology (01.03.2023)
Get more information
Journal Article
Potential limitations of the NSG humanized mouse as a model system to optimize engineered human T cell therapy for cancer
Alcantar-Orozco, Erik M, Gornall, Hannah, Baldan, Vania, Hawkins, Robert E, Gilham, David E
Published in Human gene therapy. Part B. Methods (01.10.2013)
Published in Human gene therapy. Part B. Methods (01.10.2013)
Get more information
Journal Article